Travere Therapeutics Financial Ratios
NASDAQ: TVTXHealth CareBiotechnology: Pharmaceutical PreparationsUSD
52.13+0.085 (+0.16%)
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Travere Therapeutics ratio analysis
Travere Therapeutics earned a net margin of -5.2% in FY 2025, up from -137.9% a year earlier. Gross margin was 97.9% compared with a median of 96.7% over the prior 9 years. Return on equity reached -22.2%, meaning Travere Therapeutics generated -0.22 dollars of profit for every dollar of shareholders' equity.
Valuation ratios use the closing share price on each fiscal year-end date and diluted shares from the income statement; profitability and leverage ratios use reported annual figures. Current valuation multiples are on the statistics page.
Summary generated from market data by MetaCap's automated system. Methodology
Travere Therapeutics financial ratios (annual)
| Ratio | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Price / sales | 7.18 | 6.38 | 4.60 | 12.25 | 14.09 | 6.53 | 3.32 | 5.75 | 5.27 | 5.24 |
| Price / book | 30.70 | 25.18 | 3.32 | 31.29 | 6.15 | 6.13 | 2.63 | 2.97 | 2.79 | 2.28 |
| Gross margin | 97.9% | 96.7% | 92.1% | 96.0% | 97.1% | 96.9% | 97.0% | 96.6% | 97.7% | 96.6% |
| Operating margin | -12.8% | -138.9% | -267.2% | -292.2% | -151.3% | -88.8% | -78.3% | -48.7% | -34.7% | -43.6% |
| Net margin | -5.2% | -137.9% | -76.7% | -254.4% | -136.6% | -85.4% | -83.5% | -62.5% | -38.6% | -35.9% |
| Free cash flow margin | 7.7% | -101.8% | -193.3% | -170.4% | -15.1% | -25.0% | -33.3% | -15.6% | 4.2% | -3.6% |
| Return on equity (ROE) | -22.2% | -544.3% | -55.5% | -649.9% | -59.6% | -80.2% | -66.2% | -32.3% | -20.4% | -15.6% |
| Return on assets (ROA) | -4.2% | -54.1% | -14.1% | -41.4% | -23.2% | -27.9% | -24.2% | -14.5% | -11.5% | -9.1% |
| Current ratio | 2.74 | 2.08 | 3.47 | 3.42 | 4.70 | 4.43 | 4.50 | 4.74 | 3.80 | 3.99 |
| Revenue growth | 110.5% | 60.5% | 32.7% | -17.0% | -33.5% | 13.1% | 6.8% | 6.0% | 16.0% | 33.7% |
| EPS growth | — | — | — | — | — | — | — | — | — | -140.7% |